Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Henry Schein (HSIC) Misses Q3 Earnings, Margins Decline

Henry Schein, Inc. HSIC reported adjusted earnings per share (EPS) of 87 cents in the third quarter of 2017, up 3.6% year over year. However, adjusted EPS missed the Zacks Consensus Estimate of 90 cents by 3.33%. The year-over-year upside in earnings was driven by strong revenue growth.

Revenues in Detail

Henry Schein reported revenues of $3.16 billion in the third quarter, up 10.3% year over year and also above the Zacks Consensus Estimate of $3.05 billion. The year-over-year improvement came on the back of 8.8% growth in local currencies and 1.5% increase owing to foreign currency exchange. At local currencies, internally generated sales increased 4.8% and acquisition growth was 4%.

The company recorded sales of $2.12 billion in the North American market, up 6.2% year over year. Sales totaled $1.04 billion in the international market, up 19.9% year over year.

Segment Analysis    

Henry Schein derives revenues from four operating segments: Dental, Medical, Animal Health, and Technology and Value-added services.

In the third quarter, the company derived $1.48 billion in revenues from global Dental sales, up 11.1% year over year. This includes 9.1% growth in local currencies and 2% contribution from foreign currency exchange. At local currencies, internally generated sales increased 1.6% and acquisition growth was 7.5%. Internal growth at local currencies included 0.8% growth in North America and 3.2% rise internationally.

Henry Schein, Inc. Price, Consensus and EPS Surprise

The company's global Animal Health segment witnessed 11.7% rise in revenues to $882.6 million. This includes 9.9% growth in local currencies and 1.8% increase from foreign currency exchange. At local currencies, internally generated sales increased 8% and acquisition growth was 1.9%. The 8% internal growth in local currencies included 9% rise in North America and 6.9% improvement internationally.

Worldwide Medical revenues rose 8% year over year to $690.8 million. Growth in local currencies was 7.9%, with a 0.1% increase owing to favorable foreign exchange.

Revenues from global Technology and Value-added Services grew 4.1% to $109 million. This included 3.7% growth in local currencies and a 0.4% rise related to foreign currency exchange. Acquisitions contributed 0.7% in the quarter under review.

Margin Trend         

Gross profit increased 6.1% to $836.1 million in the reported quarter. However, gross margin declined 90 basis points (bps) from the year-ago quarter to 26.5% due to a 12% rise in cost of sales, higher than the revenue growth rate.  

Despite a 7% rise in selling, general & administrative expenses of $622.5 million, adjusted operating income improved 3.6% year over year to $213.6 million. However, adjusted operating margin contracted 40 bps year over year to 6.8% in the reported quarter.

Financial Position

Henry Schein exited third-quarter 2017 with cash and cash equivalents of $79.9 million, compared with $74.7 million at the end of second-quarter 2017. Year-to-date net cash provided by operating activities was $307.5 million, compared with $378.1 million in the year-ago period.

During the quarter under review, the company bought back approximately 1.4 million shares for almost $125 million. At the close of the third quarter, the company had $425 million authorized for repurchase of common stock.

2017 & 2018 EPS Guidance

Henry Schein updated its 2017 adjusted EPS guidance (excluding litigation settlement expenses and a fourth-quarter loss related with the company's divestiture of equity ownership in E4D Technologies). The company now expects adjusted EPS in the range of $3.59-$3.61, reflecting 8–9% growth from the 2016 adjusted EPS figure of $3.31. The previous adjusted EPS 2017 guidance range was $3.59-$3.65. The Zacks Consensus Estimate for 2017 adjusted EPS is $3.64, outside the guided range.

The company also provided the guidance for 2018 EPS. Henry Schein expects reported EPS for 2018 in the band of $3.85-$3.96, reflecting an annualized growth rate of 7-10% compared with the midpoint of the company's 2017 adjusted EPS guidance range.

Our Take

Henry Schein exited third-quarter 2017 on a mixed note. All four of the company’s operating segments recorded strong year-over-year growth. Henry Schein’s strong share gains in the North American and overseas markets along with solid revenues raise optimism.

Despite the better-than-expected revenue performance, we are disappointed with the year-over-year deterioration in Henry Schein’s gross and operating margin due to higher cost of sales and expenses.

Zacks Rank & Key Picks

Henry Schein has a Zacks Rank #3 (Hold).

A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS, Luminex Corp. LMNX and Intuitive Surgical, Inc. ISRG. Notably, PetMed and Luminex sport a Zacks Rank #1 (Strong Buy), while Intuitive Surgical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018, up 79.2% from the year-ago quarter’s 24 cents. Also, gross margin expanded 548 bps year over year to 35.2% in the reported quarter.

Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017, up 216.7% year over year. Revenues increased almost 4.1% year over year to $74.1 million.

Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
PetMed Express, Inc. (PETS): Free Stock Analysis Report
 
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
 
Luminex Corporation (LMNX): Free Stock Analysis Report
 
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research